Related Experiment Video

Updated: Mar 26, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.7K

Group II p21-activated kinases as therapeutic targets in gastrointestinal cancer

Yang-Guang Shao1, Ke Ning1, Feng Li1

  • 1Yang-Guang Shao, Ke Ning, Feng Li, Department of Cell Biology, Key Laboratory of Cell Biology, Ministry of Public Health and Key Laboratory of Medical Cell Biology, Ministry of Education, China Medical University, Shenyang 110122, Liaoning Province, China.

World Journal of Gastroenterology
|January 27, 2016
PubMed

Insights

Group II p21-activated kinases (PAKs) are crucial in cancer development. Developing selective inhibitors for these kinases is essential for effective cancer treatment, particularly for gastrointestinal cancers.

Area of Science:

  • Molecular Biology
  • Oncology
  • Drug Discovery

Background:

  • P21-activated kinases (PAKs) are key regulators in oncogenic signaling pathways.
  • PAKs are divided into group I (PAK1-3) and group II (PAK4-6), with increasing research focus on group II.
  • Group II PAKs are vital for cellular processes implicated in cancer development and progression.

Purpose of the Study:

  • To review the biological activities of group II PAKs.
  • To highlight the significance of group II PAKs in gastrointestinal cancer.
  • To discuss small-molecule inhibitors targeting group II PAKs for cancer therapy.

Main Methods:

  • Literature review of biological functions of group II PAKs.
  • Analysis of group II PAKs' role in gastrointestinal cancer.
  • Survey of existing small-molecule inhibitors for group II PAKs.

Main Results:

  • Group II PAKs are implicated in fundamental cellular processes relevant to cancer.
  • Dysregulation of group II PAKs contributes to gastrointestinal cancer development and progression.
  • Current group II PAKs inhibitors lack sufficient kinase selectivity and drug-like properties.

Conclusions:

  • Group II PAKs represent promising therapeutic targets for cancer treatment.
  • There is a critical need for isoform- and kinase-selective group II PAK inhibitors.
  • Further development of effective group II PAK inhibitors could advance gastrointestinal cancer therapy.
Keywords:
Drug targetGastrointestinal cancerGroup II p21-activated kinasesPAK4 inhibitorSignaling pathway

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.6K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.3K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.8K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K